News

Background: Transthyretin amyloidosis (ATTR) is an underdiagnosed cause of cardiomyopathy that is gaining recognition as new treatments become available. The…

The incidence and prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) increased markedly in the US between 2010 and 2023, according to a study published in…

Cardiac amyloidosis is a condition in which abnormal proteins, called amyloid, build up in the heart muscle. Over time, these deposits make the heart walls stiffer…

A computerized test that measures how quickly and accurately people perform finger tapping and hand movement tasks was able to detect subtle motor problems in…

AbstractPurposeTo provide an overview of the manifestation and diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and the treatment option acoramidis,…

AbstractBackgroundCardiac amyloidosis (CA) is an under-recognized cause of heart failure. Its prevalence in screening studies, and the extent to which selective…

AbstractThe role of autologous stem cell transplantation (ASCT) is central in AL amyloidosis and continues to be defined in the era of newer therapies. To evaluate…

Executive SummaryAnselamimab (CAEL-101) is an investigational, first-in-class fibril-reactive chimeric monoclonal antibody developed by AstraZeneca (following the…

AbstractThis electronic health record-based study highlights distinct diagnostic patterns preceding a diagnosis of light chain (AL) and wild-type transthyretin (…

AbstractBackground: Amyloidosis is an infiltrative cardiomyopathy caused by amyloid deposition into the myocardium. In recent years, recognition of this treatable…